At Real Endpoints, Rare Disease Day isn't just another awareness day—it's personal. Many of us here have been directly touched by the challenges and triumphs associated with living with a rare disease, whether through personal experience or those of friends and loved ones.
read full article ›The team at Real Endpoints has been working tirelessly to improve RE Assist, a simple, easy-to-use AI-based platform designed to solve a critical gap in the market: providing patients with real-time information about available third-party foundation dollars for prescription meds.
read full article ›As Interest Rates Begin to Drop, which Biotechs Will Get an Unfair Share of New Investment?
read full article ›Your semi-regular reminder: Healthcare. Is. Hard.
read full article ›This new Health Affairs Forefront article explains in simple language why it's past time to update the methodology underpinning how we value - and ultimately price - drugs.
read full article ›But for me the big point is: CMS has done something bold and novel – creating what could be a path to getting life-altering but extremely expensive therapies to people who simply wouldn’t be able to get them otherwise. Yes, the unknowns loom large. The biggest: will the counterparties – Medicaid plans and manufacturers – want to play?
read full article ›